Integra Lifesciences Holdings Corp
NASDAQ:IART
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.97
26.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Integra Lifesciences Holdings Corp
NASDAQ:IART
|
866.3m USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
188.3B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
187.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138.8B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
135B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
128.9B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.2B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.5B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.6B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Integra Lifesciences Holdings Corp
Glance View
Integra LifeSciences Holdings Corp., an influential player in the medical technology landscape, traces its origins back to a vision of creating life-enhancing innovations for surgical procedures. Founded in the late 1980s, Integra has evolved into a formidable presence, driven by a commitment to delivering solutions that improve patient outcomes in regenerative medicine and surgical care. The company operates primarily through two segments: the Codman Specialty Surgical and the Tissue Technologies segment. By focusing on these two areas, Integra leverages its expertise in surgical tools, neurocritical care, and advanced wound care, appealing to healthcare professionals worldwide. This strategic segmentation enables the company to cater to a diverse clientele, encompassing hospitals and other medical institutions in North America, Europe, and internationally. Integra's revenue streams are notably derived from the design, manufacture, and distribution of a comprehensive suite of products used in neurosurgery, acute wound care, and reconstructive surgery. The company's innovative products, including precision surgical instruments and biologics that promote regenerative tissue healing, are key contributors to its financial success. By continuously investing in research and development, Integra ensures the introduction of cutting-edge solutions that address the evolving needs of the healthcare industry. The company's growth strategy hinges on both organic innovation and strategic acquisitions, fostering an environment where technological advancements seamlessly integrate with expanding market reach. This symbiotic approach not only solidifies Integra's position in the med-tech arena but also underpins its growth potential in an ever-competitive healthcare sector.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Integra Lifesciences Holdings Corp is 10.2%, which is below its 3-year median of 14.7%.
Over the last 3 years, Integra Lifesciences Holdings Corp’s Operating Margin has decreased from 18.4% to 10.2%. During this period, it reached a low of 9.5% on Jun 30, 2025 and a high of 18.8% on Dec 31, 2022.